D. E. SHAW & CO, L.P. - 20 Oct 2025 SCHEDULE 13G Report for Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (KROS)

Filing Manager
D. E. SHAW & CO, L.P.
Reporting Manager
D. E. Shaw & Co., L.P.
Security
Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol
KROS
Shares outstanding
30,312,706 shares
Disclosed Ownership
1,545,948 shares
Ownership
5.1%
Form type
SCHEDULE 13G
Filing time
27 Oct 2025, 16:05:30 UTC
Date of event
20 Oct 2025
Next filing
17 Feb 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"D. E. SHAW & CO, L.P. disclosed 5.1% ownership in Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (KROS) on 20 Oct 2025."

Quick Takeaways

  • D. E. SHAW & CO, L.P. filed SCHEDULE 13G for Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (KROS).
  • Disclosed ownership: 5.1%.
  • Date of event: 20 Oct 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 27 Oct 2025, 16:05.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
D. E. Shaw & Co., L.P. 5.1% 1,545,948 0 1,545,948 /s/ Daniel R. Marcus Daniel R. Marcus / Chief Compliance Officer
D. E. Shaw & Co., L.L.C. 5% 1,537,348 0 1,537,348 /s/ Daniel R. Marcus Daniel R. Marcus / Authorized Signatory
David E. Shaw 5.1% 1,545,948 0 1,545,948 /s/ Daniel R. Marcus Daniel R. Marcus / Attorney-in-Fact for David E. Shaw

Sponsored